Gossamer Bio (GOSS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, via live webcast, with voting on director elections, auditor ratification, and executive compensation approval.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact.
Record date for voting is April 20, 2026, with 234,696,281 shares of common stock outstanding.
Voting matters and shareholder proposals
Shareholders will vote to elect two Class II directors for three-year terms expiring in 2029.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) for named executive officers.
Board recommends voting “FOR” all proposals.
Shareholder proposals for the 2027 meeting must be received by December 25, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
Board consists of seven members, with a majority deemed independent under Nasdaq rules.
Board leadership includes a combined Chairman/CEO and a lead independent director.
Three standing committees: audit, compensation, and nominating/corporate governance, all with independent members.
Director compensation includes annual retainers, committee fees, and equity awards, with recent increases to committee retainers.
Director nomination process considers diversity, experience, and independence; stockholders may recommend nominees.
Latest events from Gossamer Bio
- Seralutinib advances toward late-stage data with strong safety, efficacy, and market potential.GOSS
Barclays 27th Annual Global Healthcare Conference 20259 Jul 2026 - Seralutinib improved 6MWD and biomarkers in high-risk PAH, despite missing the primary endpoint.GOSS
Study result9 Jul 2026 - Seralutinib's phase III trial nears completion, aiming to deliver top-line data by Q4 2024.GOSS
Emerging Growth Conference 798 Jul 2026 - PROSERA phase III nears full enrollment; Q1 net loss narrows, cash runway into 2027.GOSS
Q1 20258 Jul 2026 - Seralutinib's phase III trials progress with strong safety, efficacy, and global commercialization plans.GOSS
Guggenheim Securities Inaugural Healthcare Innovation Conference8 Jul 2026 - Shareholders are asked to approve major recapitalization, new equity plans, and a reverse stock split.GOSS
Proxy filing9 Jun 2026 - Clinically meaningful PROSERA results, strong imaging data, and major debt reduction plan underway.GOSS
Q1 202621 May 2026 - Shareholders to vote on major recapitalization, equity plan expansion, and reverse stock split.GOSS
Proxy filing18 May 2026 - Convertible note exchange aims to cut debt, extend maturities, and overhaul capital structure.GOSS
Proxy filing18 May 2026